Polyunsaturated fatty acids play an important part in the structural and metabolic function of cellular membranes. One of the major polyunsaturated fatty acids is arachidonic acid. Oxygenation of arachidonic acid leads to the production of potent mediators of inflammation. [1] [2] [3] Alteration of dietary fatty acid composition may result in competition with the incorporation of arachidonic acid into the cell membrane and thereby modulate the functional qualities of the cell.
Fatty acids commonly consumed in the Western diet-for example, linoleic acid-are converted via arachidonic acid into cyclooxygenase metabolites of the 2 series, whereas leucotrienes of the 4 series are produced via the lipoxygenase pathway. Leucotrienes are potent lipid mediators, which play an important part in allergic and inflammatory reactions.' Leucotriene B4, mainly produced in neutrophils, is a strong leucocyte activator. Its effects are comparable with CSa, f-Met-Leu-Phe, and platelet activating factor and include chemotaxis, nondirected migration, aggregation, and lysosomal enzyme release. [7] [8] [9] [10] [11] [12] Polyunsaturated fatty acids with three carbon atoms from the terminal methyl group to the first double bond are designated omega-3 or n-3 fatty acids. Eicosapentaenoic acid (20:5, n-3) and docosahexaenoic acid (22:6, n-3) are the main long chain n-3 fatty acids in fish oil. Eicosapentaenoic acid incorporated in cell membrane can be converted, via the cyclooxygenase pathway, into prostaglandins, thromboxanes, and prostacyclins of the Table 1 shows median (range) concentrations at baseline and after 12 weeks of fish oil or placebo supplementation, of plasma fibrinogen, C reactive protein, serum amyloid A, and IgM rheumatoid factor and the erythrocyte sedimentation rate. The complete blood cell count was not significantly altered. Table 2 shows the differences between neutrophil leucotriene B4 production at baseline and after 12 molPo=mol/100 mol fatty acids. variables did not correlate with changes in the leucotriene production. Within four to eight weeks after discontinuation of fish oil supplementation leucotriene B5 production had fallen below the detection level again.
PLASMA CHOLESTEROL ESTERS AND NEUTROPHIL MEMBRANE PHOSPHOLIPIDS
In the placebo period no significant alterations were observed in the fatty acid composition of the plasma cholesterol ester fraction. Figure 1 shows the course of the composition of selected fatty acids in the plasma cholesterol ester fraction during the study. The omega-3 fatty acid incorporation reached a maximum within one month of fish oil administration. In all cases these values persisted during the fish oil period. In the plasma cholesterol ester fraction the omega-3 fatty acids replaced mainly the omega-6 fatty acids: linoleic acid (18:2, n-6), y-linolenic acid (18:3, n-6), and dihomo-y-linolenic acid (20:3, n-6). The amount of arachidonic acid (20:4, n-6), however, significantly increased. Figure 2 shows the differences between incorporation of relative amounts of selected fatty acids in the plasma cholesterol ester fraction and in the total phospholipid and sphingolipid fraction of isolated neutrophils before and during 12 weeks of fish oil supplementation. Owing to technical difficulties the fatty acid composition of neutrophil membrane phospholipids was calculated for only nine patients. In both fractions 20:5, n-3 was signifi- cantly incorporated (p<001). In contrast with the increase of22:6, n-3 in the plasma cholesterol ester fraction (p<001), the increment ofrelative amounts of 22:6, n-3 in the membrane phospholipids during fish oil supplementation was not statistically significant. The 20:4, n-6 content in the neutrophil membrane phospholipids was also not significantly altered during fish oil supplementation. 14 g fish oil (3-5 g 20:5, n-3), in healthy volunteers. In our trial 6 g fish oil (2-04 g 20:5, n-3) had no influence of statistical importance either on the mean plasma fibrinogen concentration or on the plasma concentration of other acute phase proteins like C reactive protein and serum amyloid A. A possible explanation for these apparently conflicting findings may be that fibrinogen synthesis is dependent on the dose of fish oil.
Discussion
Despite the unchanged concentrations of acute phase proteins, fish oil supplementation results in changes in the leucotriene production of in vitro stimulated neutrophils. A small production of leucotriene B5 was observed, concomitant with a decrease of the mean leucotriene B4 production. The slight production of leucotriene B5 is in accordance with the small amounts of 20:5, n-3 incorporated in the total phospholipid and sphingolipid fraction from isolated neutrophils. A major uncertainty is whether any of the induced alterations of leucotriene contribute to the result of clinical improvement during fish oil treatment. As no correlations were found between changes in the leucotriene production and the significantly altered disease variables it seems unlikely that inhibition of the lipoxygenase pathway is the only cause of clinical improvement. As fish oil modulates the formation of leucotrienes, prostacyclin, and prostaglandins it is possible that the effects of fish oil may be a result of changes in the production of the prostaglandins. It is interesting to note, however, that even during the use of non-steroidal anti-inflammatory drugs, which block prostaglandin synthesis, fish oil provides an additive beneficial effect.
In conclusion this study shows that administration of omega-3 fatty acids is effective in suppressing clinical symptoms of rheumatoid arthritis. Convincing biochemical evidence that omega-3 fatty acids may also act as a disease modifying drug were not obtained, however. Although a change in neutrophil leucotriene production in vitro could be clearly shown, the question remains whether the clinical effects can be accounted for by inhibition of the lipoxygenase pathway. 
